Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience (NYSE:ANRO) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $28.00 price target on the stock, up previously from $27.00.
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment [Yahoo! Finance]
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment